Summary of the proceedings of the 40th Annual General Meeting of the Company held on 18th July, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jenburkt Pharmaceuticals held its 40th AGM on 18th July 2025 via video conferencing, which ran from around 3:30 PM to 4:37 PM after a brief delay due to a technical glitch. The Chairman reviewed the company's FY2024-25 performance across its India and international businesses, highlighted the reorganisation of the pharma division into two focused units called NOVA and ZORA, and mentioned a strategic tie-up with NIMHANS and progress in the wellness division. He also flagged the company's focus on innovation, artificial intelligence integration, and sustainability. Shareholders raised questions on financial results, products, and markets, which were addressed in detail. The statutory and secretarial auditors' reports had no adverse qualifications, and all six resolutions placed before the meeting were approved.
Shareholders approved a strong dividend of ₹18 per share (180% on face value of ₹10) for FY2024-25 and re-appointed Ashish U. Bhuta as Chairman and Managing Director, signalling continuity in leadership. The clean audit reports and forward-looking focus on AI and portfolio reorganisation are mildly positive signals for the stock.